Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Research context
Sequana Medical NV appears in PyInvesting’s Brussels Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Sequana Medical NV is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 121.6.
Sequana Medical NV's total revenue rose by 6.6% to $595K since the same quarter in the previous year.
Its net income has dropped by 24.5% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.1% to $-4M since the same quarter in the previous year.
Based on the above factors, Sequana Medical NV gets an overall score of 2/5.